Bristol Myers Opdivo approval spurs trading volume despite share decline
FDA expands flagship cancer drug to untreated Hodgkin lymphoma, potentially adding billions in revenue as institutional investors take positions
Bristol Myers Squibb shares fell 1.1% to $57.48 on Friday despite a significant regulatory victory for the pharmaceutical giant, as trading volume surged more than five-fold to 65.8 million shares—well above the company's 12 million-share daily average. The heavy volume suggests institutional positioning around the expanded approval of Opdivo, Bristol Myers' flagship cancer immunotherapy.
The U.S. Food and Drug Administration approved Opdivo in combination with chemotherapy for previously untreated Stage III or IV classical Hodgkin lymphoma in adult and pediatric patients aged 12 and older. The approval marks a significant expansion for the drug, which was previously approved only for relapsed or refractory cases of the blood cancer.
The regulatory decision was based on findings from the Phase 3 SWOG 1826 study, which demonstrated a 58% reduction in the risk of disease progression or death compared to standard care. At median follow-up of 13.7 months, progression-free survival had not been reached in either arm, with outcomes favoring the Opdivo combination.
"This approval represents a potential new standard of care in the frontline treatment of advanced classical Hodgkin lymphoma," according to analysts who track the company's oncology pipeline. The expansion into earlier-line treatment is expected to become a major commercial growth driver for Bristol Myers.
The Hodgkin lymphoma market is projected to reach $20.8 billion by 2035, with a compound annual growth rate of 10.5% from 2025 to 2035, driven by increasing prevalence and the adoption of targeted therapies like checkpoint inhibitors. Moving Opdivo into the first-line setting positions Bristol Myers to capture a significant portion of this expanding market.
Bristol Myers, with a market capitalization of $118 billion, has faced pressure in recent years as patent expirations loom for key drugs. The company's forward price-to-earnings ratio of 9.5 reflects investor concerns about revenue growth, but analysts maintain an average target price of $62.72, representing roughly 9% upside from current levels.
The stock currently trades below its 50-day moving average of $58.44 but remains above its 200-day moving average of $50.28, suggesting the longer-term uptrend remains intact despite recent volatility. The company's dividend yield of 4.19% provides additional income support for shareholders.
Safety data from the clinical trial showed serious adverse reactions occurred in 39% of patients receiving Opdivo with chemotherapy, with the most frequent including peripheral neuropathy, neutropenia, and fever. Three fatal adverse reactions, primarily from sepsis, were reported in the trial.
Opdivo has been a cornerstone of Bristol Myers' oncology portfolio since its initial accelerated approval in 2016 for relapsed Hodgkin lymphoma. The drug generated substantial revenue for the company, though exact figures for the lymphoma indication are not broken out separately in financial reports.
The expanded approval comes as Bristol Myers seeks to refresh its pipeline and offset patent losses. The company also secured European approval for the same indication, broadening the commercial opportunity across major markets. With 83% of shares held by institutional investors, today's volume spike suggests portfolio managers are actively reassessing the company's growth prospects following the regulatory win.